Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

NCT02552953 is registered in ClinicalTrials.gov with Cyclacel Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02552953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02552953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2015
Completion date
August 25, 2023
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer